A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

A method of preventing or treating an inflammatory disease including diabetes type 1 and type 2 in a subject in need thereof is provided. Also provided are pharmaceutical compositions, articles and foods for the treatment of an inflammatory disease.

A method of preventing or treating an inflammatory disease including diabetes type 1 and type 2 in a subject in need thereof is provided. Also provided are pharmaceutical compositions, articles and foods for the treatment of an inflammatory disease.

Described, among other things, are dosage form for administration to a subject, the dosage forms having at least four ingredients selected from okra, quercetin, gypenosides from Gynostemma pentaphyllum, punicalagins from pomegranate, zinc gluconate, chromium picolinate, curcuminoids, cinnamon Ceylon, mangiferin, Gymnema sylvestre extract, Schisandra chinensis, bitter melon, and Costus igneus. Upon administration to a mammalian subject, the dosage forms generally promote the subject's health through the maintenance of a healthy blood sugar level.

Described, among other things, are dosage form for administration to a subject, the dosage forms having at least four ingredients selected from okra, quercetin, gypenosides from Gynostemma pentaphyllum, punicalagins from pomegranate, zinc gluconate, chromium picolinate, curcuminoids, cinnamon Ceylon, mangiferin, Gymnema sylvestre extract, Schisandra chinensis, bitter melon, and Costus igneus. Upon administration to a mammalian subject, the dosage forms generally promote the subject's health through the maintenance of a healthy blood sugar level.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.

A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.